Literature DB >> 16959375

CRH inhibits NF-kappa B signaling in human melanocytes.

Blazej Zbytek1, Lawrence M Pfeffer, Andrzej T Slominski.   

Abstract

Corticotropin releasing hormone (CRH), a messenger of stress at the central level, is expressed in the epidermis where it operates within local equivalent of hypothalamo-pituitary axis. CRH inhibits NF-kappaB activity in human immortalized epidermal (PIG1) melanocytes. In melanocytes CRH stimulates pro-opiomelanocortin (POMC) mRNA and adrenocorticotropin (ACTH) peptide production. Knockdown of POMC levels by transfecting cells with antisense oligonucleotides blocks the effect of CRH on NF-kappaB signaling indicating that the above inhibition is indirect, e.g. through activation of POMC. We suggest that induction of POMC by CRH serves as a feedback mechanism to self-restrict inflammatory response in the skin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16959375      PMCID: PMC1839005          DOI: 10.1016/j.peptides.2006.07.017

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  46 in total

Review 1.  Shaping the nuclear action of NF-kappaB.

Authors:  Lin-Feng Chen; Warner C Greene
Journal:  Nat Rev Mol Cell Biol       Date:  2004-05       Impact factor: 94.444

Review 2.  Regulation of proopiomelanocortin gene expression in pituitary.

Authors:  J R Lundblad; J L Roberts
Journal:  Endocr Rev       Date:  1988-02       Impact factor: 19.871

3.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

Review 4.  Mast cells as targets of corticotropin-releasing factor and related peptides.

Authors:  Theoharis C Theoharides; Jill M Donelan; Nikoletta Papadopoulou; Jing Cao; Duraisamy Kempuraj; Pio Conti
Journal:  Trends Pharmacol Sci       Date:  2004-11       Impact factor: 14.819

Review 5.  Melanin pigmentation in mammalian skin and its hormonal regulation.

Authors:  Andrzej Slominski; Desmond J Tobin; Shigeki Shibahara; Jacobo Wortsman
Journal:  Physiol Rev       Date:  2004-10       Impact factor: 37.312

6.  Molecular mechanisms of the effect of herpesvirus saimiri protein StpC on the signaling pathway leading to NF-kappaB activation.

Authors:  Elena M Sorokina; Joseph J Merlo; Alexander Y Tsygankov
Journal:  J Biol Chem       Date:  2004-01-14       Impact factor: 5.157

7.  Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes.

Authors:  Blazej Zbytek; Lawrence M Pfeffer; Andrzej T Slominski
Journal:  J Endocrinol       Date:  2004-06       Impact factor: 4.286

Review 8.  Role of regulatory factors in pituitary tumour formation.

Authors:  Marta Korbonits; Damian G Morris; Alexandra Nanzer; Blerina Kola; Ashley B Grossman
Journal:  Front Horm Res       Date:  2004       Impact factor: 2.606

9.  Anti-inflammatory drugs and tumor necrosis factor-alpha production from monocytes: role of transcription factor NF-kappa B and implication for rheumatoid arthritis therapy.

Authors:  Luisa Lavagno; Gabriele Gunella; Claudio Bardelli; Simona Spina; Luigia Grazia Fresu; Ilario Viano; Sandra Brunelleschi
Journal:  Eur J Pharmacol       Date:  2004-10-06       Impact factor: 4.432

10.  Immunosuppressive activity of corticotrophin-releasing factor. Inhibition of interleukin-1 and interleukin-6 production by human mononuclear cells.

Authors:  P Hagan; S Poole; A F Bristow
Journal:  Biochem J       Date:  1992-01-01       Impact factor: 3.857

View more
  27 in total

Review 1.  Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction.

Authors:  Dimitris K Grammatopoulos
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Neuroendocrinology of the skin: An overview and selective analysis.

Authors:  Michal A Zmijewski; Andrzej T Slominski
Journal:  Dermatoendocrinol       Date:  2011-01

3.  20,23-dihydroxyvitamin D3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes.

Authors:  Zorica Janjetovic; Robert C Tuckey; Minh N Nguyen; Edwin M Thorpe; Andrzej T Slominski
Journal:  J Cell Physiol       Date:  2010-04       Impact factor: 6.384

Review 4.  Steroidogenesis in the skin: implications for local immune functions.

Authors:  Andrzej Slominski; Blazej Zbytek; Georgios Nikolakis; Pulak R Manna; Cezary Skobowiat; Michal Zmijewski; Wei Li; Zorica Janjetovic; Arnold Postlethwaite; Christos C Zouboulis; Robert C Tuckey
Journal:  J Steroid Biochem Mol Biol       Date:  2013-02-19       Impact factor: 4.292

Review 5.  Inflammation in Epileptic Encephalopathies.

Authors:  Oleksii Shandra; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Adv Protein Chem Struct Biol       Date:  2017-02-28       Impact factor: 3.507

Review 6.  Stress-related skin disorders.

Authors:  Alex Alexopoulos; George P Chrousos
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 7.  ROS and SOCE: recent advances and controversies in the regulation of STIM and Orai.

Authors:  Ivan Bogeski; Tatiana Kilch; Barbara A Niemeyer
Journal:  J Physiol       Date:  2012-05-21       Impact factor: 5.182

Review 8.  Emerging role of alternative splicing of CRF1 receptor in CRF signaling.

Authors:  Michał A Zmijewski; Andrzej T Slominski
Journal:  Acta Biochim Pol       Date:  2010-03-16       Impact factor: 2.149

9.  Bioactive forms of vitamin D selectively stimulate the skin analog of the hypothalamus-pituitary-adrenal axis in human epidermal keratinocytes.

Authors:  Justyna M Wierzbicka; Michał A Żmijewski; Anna Piotrowska; Boguslaw Nedoszytko; Magdalena Lange; Robert C Tuckey; Andrzej T Slominski
Journal:  Mol Cell Endocrinol       Date:  2016-08-12       Impact factor: 4.102

10.  On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders.

Authors:  A Slominski
Journal:  Br J Dermatol       Date:  2009-02       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.